Gynecologic oncology · 2025
Comparison of breast and gastric HER2 immunohistochemistry (IHC) scoring criteria in the assessment of endometrial carcinoma.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Furuya Rachel L, Grither Whitney, Evans Mark G, Wu Sharon, Hechtman Jaclyn F, Krause Harris B, Elliott Andrew, Mathews Cara, Oliver Matthew T, Miller Katherine, Wei Shuanzeng, Ali-Fehmi Rouba, Bryant David A, Oberley Matthew J, Powell Matthew A, Thaker Premal H
Аннотация
BACKGROUND: Immunohistochemistry (IHC) testing is the primary method to determine HER2 status at many institutions, often with reflex to in situ hybridization (ISH). DNA- and RNA- based platforms are emerging for HER-2 assessment. While approved IHC algorithms exist for HER2 scoring in breast and gastric carcinomas, neither has been validated in endometrial cancer. This study seeks to compare them and evaluate patterns of DNA and RNA expression.
METHODS: 263 endometrioid endometrial adenocarcinoma (EEA), 275 serous endometrial carcinoma (SEC), and 214 uterine carcinosarcoma (UCS) specimens were randomly selected. Previously stained HER2 IHC slides underwent blinded review by two board-certified pathologists and were scored utilizing gastric and breast criteria. Tumors were analyzed for ERBB2 copy number amplification by DNA sequencing and ERBB2 RNA expression by RNA sequencing. Statistical significance was determined using unpaired t-test.
RESULTS: Concordance between scoring algorithms was high for HER2-positive (95 %) and HER2-negative (88 %) cases. Of discordant tumors, the majority (89.7 % of EEA, 68.8 % of SEC, and 81.8 % of UCS) were negative by breast but equivocal by gastric criteria. RNA expression levels were significantly different between discordant cases and negative cases and between negative and equivocal cases. HER2-positivity was associated with worse survival in EEC, improved in SEC, and no difference in UCS.
CONCLUSIONS: Breast and gastric scoring criteria show high concordance in endometrial carcinoma, with discordance primarily in equivocal tumors. RNA expression may help stratify equivocal from negative cases. Further study is needed to determine whether HER2 alterations at the DNA, RNA, or protein level predict response to newer generation HER2-targeted therapies.
METHODS: 263 endometrioid endometrial adenocarcinoma (EEA), 275 serous endometrial carcinoma (SEC), and 214 uterine carcinosarcoma (UCS) specimens were randomly selected. Previously stained HER2 IHC slides underwent blinded review by two board-certified pathologists and were scored utilizing gastric and breast criteria. Tumors were analyzed for ERBB2 copy number amplification by DNA sequencing and ERBB2 RNA expression by RNA sequencing. Statistical significance was determined using unpaired t-test.
RESULTS: Concordance between scoring algorithms was high for HER2-positive (95 %) and HER2-negative (88 %) cases. Of discordant tumors, the majority (89.7 % of EEA, 68.8 % of SEC, and 81.8 % of UCS) were negative by breast but equivocal by gastric criteria. RNA expression levels were significantly different between discordant cases and negative cases and between negative and equivocal cases. HER2-positivity was associated with worse survival in EEC, improved in SEC, and no difference in UCS.
CONCLUSIONS: Breast and gastric scoring criteria show high concordance in endometrial carcinoma, with discordance primarily in equivocal tumors. RNA expression may help stratify equivocal from negative cases. Further study is needed to determine whether HER2 alterations at the DNA, RNA, or protein level predict response to newer generation HER2-targeted therapies.